Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr

Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal

Kimberly-Clark to acquire Kenvue in $48.7 billion mega deal

Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%

Cipla to acquire Inzpera Healthsciences for Rs. 110.65 Cr

The transaction is expected to be completed within one month from the signing of the definitive agreements.

Industry leaders call for a new era of collaboration, innovation, and self-reliance

Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence

Merck Foundation launches $22 million initiative to improve cardiovascular care in US

Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country

Jubilant Pharmova posts consolidated Q2 FY26 PAT at Rs. 120.3 Cr

Dr Lal Path Labs reports consolidated Q2 FY26 PAT at Rs. 150.6 Cr

The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025

Indegene posts consolidated Q2 FY26 PAT at Rs. 102.1 Cr

Dr Agarwals Health Care posts consolidated Q2 FY26 PAT at Rs. 29.69 Cr

Dr Agarwals Health Care has reported total income of Rs. 506.62 crore during the period ended September 30, 2025

Dabur India reports consolidated Q2 FY26 PAT at Rs. 452.55 Cr

Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025

Dr. Agarwals Eye Hospital posts consolidated Q2 FY26 PAT at Rs. 19.32 Cr

Dr Agarwals Eye Hospital has reported total income of Rs. 118.40 crore during the period ended September 30, 2025

Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr

Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025

Tatva Chintan Pharma Chem reports consolidated Q2 FY26 PAT at Rs. 9.91 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025

Indraprastha Medical Corporation posts consolidated Q2 FY26 PAT at Rs. 49.46 Cr

Indraprastha Medical Corporation has reported total income of Rs. 388.40 crore during the period ended September 30, 2025

MedPlus Health Services posts consolidated Q2 FY26 PAT at Rs. 55.50 Cr

Medplus Health Services has reported total income of Rs. 1,696.79 crore during the period ended September 30, 2025

Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion

Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter

Merck’s Capvaxive shows strong momentum amid industry vaccine decline

Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials

Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio